Graph AI Raises $3 Mn To Automate Drug Safety Monitoring for Pharma Firms
Pharmaceutical-sector focussed AI startup Graph AI has secured $3 Mn (around INR 26.37 Cr) in its seed funding round led by Bessemer Venture Partners.
In a statement, the startup said it will use the funds for product innovation, team expansion, and fast-tracking market adoption for its proprietary pharmacovigilance automation platform.
Pharmacovigilance, which is mandated by global drug regulatory authorities, requires pharmaceutical companies to continuously monitor, detect, and report ADE across a drug’s entire lifecycle, from clinical trials to post-market use.
However, this $8 Bn market is fragmented and labour intensive, with companies generally relying on service firms to manually extract and process data from a wide range of unstructured sources, call centre transcripts, legal filings, medical literature, emails, and social media posts.
Graph AI claims Graph Safety fixes this problem through its “context-aware” AI. Graph AI said its platform is being used by enterprises and it has built a pipeline of over 7,000 marketed drugs.
The funding round comes as AI-powered solutions are reshaping the drug safety and compliance landscape. Healthtech innovators are also using AI for chatbots, telemedicine platforms, and wearable data analysis to enhance accessibility and real-time monitoring, bridging critical gaps in the healthcare landscape.
These startups are seeing strong interest from investors.
The post Graph AI Raises $3 Mn To Automate Drug Safety Monitoring for Pharma Firms appeared first on Inc42 Media.